AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15776198 — intervention group
Group type: COMPARATOR
Intervention: 830 nm wavelength infrared diode laser
Number of subjects: 40
Study 12229939 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial ileal bypass surgery (intervention group)
Number of subjects: 838
Study 12229939 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surgical intervention)
Number of subjects: 838
Study 9585312 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg followed by thiopental 4-6 mg/kg; intubation after 45 s (Group 1)
Number of subjects: 45
Study 9585312 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg followed by thiopental 4-6 mg/kg; intubation after 60 s (Group 2)
Number of subjects: 45
Study 9585312 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium 0.01 mg/kg followed by thiopental and succinylcholine 1.5 mg/kg; intubation after 60 s (Group 3)
Number of subjects: 45
Study 7892923 — intervention group
Group type: EXPERIMENTAL
Intervention: Free preventive visits to physicians under Medicare waivers
Number of subjects: 4195
Study 7892923 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preventive visits)
Number of subjects: 4195
Study 2514993 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-gauge needle
Number of subjects: 152
Study 2514993 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-gauge needle
Number of subjects: 152
Study 2514993 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-gauge needle
Number of subjects: 152
Study 72192 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral non-absorbed antibiotics
Number of subjects: 113
Study 72192 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 113
Study 30925280 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led decision coaching with evidence-based decision aid
Number of subjects: 64
Study 30925280 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 64
Study 26909662 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 108
Study 26909662 — intervention group
Group type: COMPARATOR
Intervention: Nutrition education
Number of subjects: 108
Study 26909662 — intervention group
Group type: COMPARATOR
Intervention: Exercise plus nutrition education
Number of subjects: 108
Study 26035743 — intervention group
Group type: EXPERIMENTAL
Intervention: Withholding breastfeeding (one hour before through one hour after vaccination)
Number of subjects: 400
Study 26035743 — intervention group
Group type: COMPARATOR
Intervention: Immediate breastfeeding at the time of vaccination
Number of subjects: 400
Study 23866300 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 20‐160 mg/day
Number of subjects: 20
Study 23866300 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine 5‐20 mg/day
Number of subjects: 20
Study 21653904 — intervention group
Group type: EXPERIMENTAL
Intervention: Active bupropion SR and 11 sessions of CBT for 40 weeks (A-CBT)
Number of subjects: 406
Study 21653904 — intervention group
Group type: EXPERIMENTAL
Intervention: Active bupropion SR for 40 weeks
Number of subjects: 406
Study 21653904 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo and 11 sessions of CBT for 40 weeks
Number of subjects: 406
Study 21653904 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 40 weeks
Number of subjects: 406
Study 21653904 — intervention group
Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 406
Study 19184081 — intervention group
Group type: EXPERIMENTAL
Intervention: latanoprost
Number of subjects: 58
Study 19184081 — intervention group
Group type: COMPARATOR
Intervention: dorzolamide/timolol
Number of subjects: 58
Study 16928196 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity treadmill training (TMT), n=7
Number of subjects: 18
Study 16928196 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON), n=6
Number of subjects: 18
Study 15116057 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m²)
Number of subjects: 7
Study 15116057 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (10 mg/m²) with ketoconazole (200 mg once daily for 3 days)
Number of subjects: 7
Study 11702016 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HT(6) C267T genetic variant
Number of subjects: 57
Study 11702016 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant treatment
Number of subjects: 57
Study 9453428 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (1 g per day orally)
Number of subjects: 15
Study 9453428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8941543 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric training (CTG)
Number of subjects: 54
Study 8941543 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training (ETG)
Number of subjects: 54
Study 8941543 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 54
Study 2183879 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.12 mg/kg
Number of subjects: 82
Study 2183879 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.20 mg/kg
Number of subjects: 82
Study 2183879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 6251644 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (INTAL)
Number of subjects: 55
Study 30629285 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metoclopramide 10 mg
Number of subjects: 148
Study 30629285 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 148
Study 27984250 — intervention group
Group type: EXPERIMENTAL
Intervention: Music group (listened to preferred music)
Number of subjects: 100
Study 27984250 — intervention group
Group type: COMPARATOR
Intervention: Control group (listened to no music)
Number of subjects: 100
Study 25524831 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) 130/0.42
Number of subjects: 798
Study 25524831 — intervention group
Group type: COMPARATOR
Intervention: Ringer's acetate
Number of subjects: 798
Study 23438139 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A palmitate and antioxidant-containing oil-based moisturizer
Number of subjects: 0
Study 23438139 — intervention group
Group type: COMPARATOR
Intervention: No-treatment group
Number of subjects: 0
Study 21277840 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted pulse amplitude TENS
Number of subjects: 56
Study 21277840 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed pulse amplitude TENS
Number of subjects: 56
Study 21277840 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 56
Study 21277840 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 56
Study 19961453 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA stored in normal saline (NS) for 1 week (Group A1)
Number of subjects: 24
Study 19961453 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA stored in phosphate buffer saline (PBS) for 1 week (Group A2)
Number of subjects: 24
Study 19961453 — intervention group
Group type: EXPERIMENTAL
Intervention: NEC stored in normal saline (NS) for 1 week (Group B1)
Number of subjects: 24
Study 19961453 — intervention group
Group type: EXPERIMENTAL
Intervention: NEC stored in phosphate buffer saline (PBS) for 1 week (Group B2)
Number of subjects: 24
Study 17967711 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional intravascular ultrasound (IVUS) imaging
Number of subjects: 88
Study 17967711 — intervention group
Group type: COMPARATOR
Intervention: Quantitative cineangiographic analysis (QCA)
Number of subjects: 88
Study 17967711 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-treated diabetic patients
Number of subjects: 88
Study 17967711 — intervention group
Group type: COMPARATOR
Intervention: Non-insulin-treated diabetic patients
Number of subjects: 88
Study 15136070 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg daily
Number of subjects: 25
Study 15136070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 11230834 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide with heparin
Number of subjects: 6977
Study 11230834 — intervention group
Group type: COMPARATOR
Intervention: Placebo with heparin
Number of subjects: 6977
Study 11230834 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide without heparin
Number of subjects: 6977
Study 11230834 — intervention group
Group type: COMPARATOR
Intervention: Placebo without heparin
Number of subjects: 6977
Study 11230834 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 6977
Study 11230834 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 6977
Study 8963818 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.00-mm diameter zones
Number of subjects: 60
Study 8963818 — intervention group
Group type: COMPARATOR
Intervention: 5.00-mm zones
Number of subjects: 60
Study 8963818 — intervention group
Group type: COMPARATOR
Intervention: 5.00- to 6.00-mm multizone treatment
Number of subjects: 60
Study 1465561 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraphat
Number of subjects: 112
Study 1465561 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrabond
Number of subjects: 112
Study 1465561 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment of Duraphat failures with Vitrabond
Number of subjects: 112
Study 1465561 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment of Vitrabond failures with Duraphat
Number of subjects: 112
Study 6608581 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam (200 mg/kg/day)
Number of subjects: 34
Study 6608581 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin (400 mg/kg/day) plus chloramphenicol (75 mg/kg/day)
Number of subjects: 34
Study 30642194 — intervention group
Group type: EXPERIMENTAL
Intervention: Home assessment visit by an occupational therapist prior to discharge
Number of subjects: 77
Study 29218680 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine 40 mg/day
Number of subjects: 400
Study 29218680 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine 80 mg/day
Number of subjects: 400
Study 29218680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 29218680 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine (both dosages)
Number of subjects: 400
Study 29218680 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine (up to 48 weeks)
Number of subjects: 400
Study 26307133 — intervention group
Group type: EXPERIMENTAL
Intervention: CPS therapy (Carboplatin, Paclitaxel, and Sorafenib)
Number of subjects: 119
Study 26307133 — intervention group
Group type: COMPARATOR
Intervention: CP therapy (Carboplatin and Paclitaxel)
Number of subjects: 119
Study 24481213 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit SBP variability (highest decile)
Number of subjects: 5880
Study 22178164 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound-guided embryo aspiration plus local administration of low-dose methotrexate (MTX)
Number of subjects: 68
Study 22178164 — intervention group
Group type: COMPARATOR
Intervention: Systemic administration of MTX plus curettage with hysteroscopy (control group)
Number of subjects: 68
Study 21146010 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of antibiotics during CVAP placement
Number of subjects: 459
Study 21146010 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics during CVAP placement
Number of subjects: 459
Study 17096683 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (4 mg kg(‐1) infusion for 20 min)
Number of subjects: 37
Study 17096683 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 37
Study 16076867 — intervention group
Group type: EXPERIMENTAL
Intervention: NPM1 mutations
Number of subjects: 401
Study 16076867 — intervention group
Group type: EXPERIMENTAL
Intervention: NPM1+/FLT3‐LM‐ mutations
Number of subjects: 401
Study 16076867 — intervention group
Group type: COMPARATOR
Intervention: NPM1+/FLT3‐LM+
Number of subjects: 401
Study 12000813 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate surgical repair of the aneurysm
Number of subjects: 1136
Study 12000813 — intervention group
Group type: COMPARATOR
Intervention: Surveillance (ultrasonography or CT every six months)
Number of subjects: 1136
Study 10533479 — intervention group
Group type: EXPERIMENTAL
Intervention: Third intensification block of chemotherapy (including dexamethasone)
Number of subjects: 18
Study 10533479 — intervention group
Group type: COMPARATOR
Intervention: Continuing chemotherapy
Number of subjects: 18
Study 7762325 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppressive therapy
Number of subjects: 28
Study 7762325 — intervention group
Group type: COMPARATOR
Intervention: Nonsuppressed nodules
Number of subjects: 28
Study 7762325 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat FNA (with or without suppressive therapy)
Number of subjects: 28
Study 2025190 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcuticular non-absorbable polypropylene 'prolene' suture
Number of subjects: 66
Study 2025190 — intervention group
Group type: COMPARATOR
Intervention: Metal skin staples
Number of subjects: 66
Study 2025190 — intervention group
Group type: COMPARATOR
Intervention: Metal skin staples (removed at 10 days)
Number of subjects: 66
Study 2025190 — intervention group
Group type: COMPARATOR
Intervention: Metal skin staples (removed at 14 days)
Number of subjects: 66
Study 7027890 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 52
Study 7027890 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 52
Study 31553438 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg/day orally)
Number of subjects: 172
Study 31553438 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (80 mg/m2 intravenously) plus Docetaxel (60 mg/m2 i.v.)
Number of subjects: 172
Study 28318455 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope Ranger video laryngoscope
Number of subjects: 20
Study 28318455 — intervention group
Group type: COMPARATOR
Intervention: Macintosh direct laryngoscope
Number of subjects: 20
Study 28318455 — intervention group
Group type: EXPERIMENTAL
Intervention: King Vision video laryngoscope
Number of subjects: 20
Study 26837508 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral osteotomy following tip plasty
Number of subjects: 65
Study 26837508 — intervention group
Group type: COMPARATOR
Intervention: Lateral osteotomy before tip plasty
Number of subjects: 65
Study 24313636 — intervention group
Group type: EXPERIMENTAL
Intervention: Propess (intact membranes)
Number of subjects: 169
Study 24313636 — intervention group
Group type: EXPERIMENTAL
Intervention: Propess (natural rupture)
Number of subjects: 169
Study 22128294 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (800 µg vaginally) after 200 mg mifepristone
Number of subjects: 20
Study 22128294 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy women)
Number of subjects: 20
Study 19243721 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation of the atlanto-occipital joint
Number of subjects: 37
Study 19243721 — intervention group
Group type: COMPARATOR
Intervention: Manual contact placebo intervention (Control)
Number of subjects: 37
Study 17576325 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 400 mg ketoconazole
Number of subjects: 90
Study 17576325 — intervention group
Group type: COMPARATOR
Intervention: Two doses of 300 mg fluconazole with 2 weeks interval
Number of subjects: 90
Study 15168391 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF (1,000 mg) + Ferrous sulfate (105 mg) coadministered
Number of subjects: 10
Study 15168391 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF (1,000 mg) + Ferrous sulfate (4 hours later)
Number of subjects: 10
Study 15168391 — intervention group
Group type: COMPARATOR
Intervention: MMF (1,000 mg) alone (control)
Number of subjects: 10
Study 11452246 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.4 mg, 1.2 mg, and 3.6 mg administered intraligamentarily
Number of subjects: 0
Study 11452246 — intervention group
Group type: COMPARATOR
Intervention: Morphine 1.2 mg administered subcutaneously
Number of subjects: 0
Study 11452246 — intervention group
Group type: COMPARATOR
Intervention: Morphine 1.2 mg and Fentanyl 50 microg administered submucosally
Number of subjects: 0
Study 9570649 — intervention group
Group type: EXPERIMENTAL
Intervention: S. boulardii 113 g twice daily
Number of subjects: 72
Study 9570649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 7799581 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined endolymphatic therapy (lymph irradiation with helium-neon laser and direct endolymphatic antibacterial therapy)
Number of subjects: 25
Study 7799581 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study 3207542 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 40 mg
Number of subjects: 60
Study 3207542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31455324 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile outreach team treatment (DOTS regime)
Number of subjects: 200
Study 31455324 — intervention group
Group type: COMPARATOR
Intervention: Facility-based DOTS treatment
Number of subjects: 200
Study 31455324 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile outreach team treatment
Number of subjects: 200
Study 31455324 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Mobile outreach and Facility-based)
Number of subjects: 200
Study 28458075 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Number of subjects: 255
Study 28458075 — intervention group
Group type: COMPARATOR
Intervention: Health Education
Number of subjects: 255
Study 28458075 — intervention group
Group type: COMPARATOR
Intervention: Brief Advice to quit
Number of subjects: 255
Study 26243363 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity progressive resistance training (HiPRT) with impact loading (n=12)
Number of subjects: 28
Study 22747323 — intervention group
Group type: EXPERIMENTAL
Intervention: RRGI (deep breathing, relaxation response, meditation, and guided imagery techniques)
Number of subjects: 52
Study 22747323 — intervention group
Group type: EXPERIMENTAL
Intervention: CB (cognitive behavioral techniques)
Number of subjects: 52
Study 22747323 — intervention group
Group type: EXPERIMENTAL
Intervention: RRGICB (combination of RRGI and CB)
Number of subjects: 52
Study 22747323 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 21309489 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at target effect-site concentration (Ce) of 0.5 ng/ml
Number of subjects: 104
Study 21309489 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at target effect-site concentration (Ce) of 1 ng/ml
Number of subjects: 104
Study 21309489 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at target effect-site concentration (Ce) of 2 ng/ml
Number of subjects: 104
Study 21309489 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at target effect-site concentration (Ce) of 4 ng/ml
Number of subjects: 104
Study 17635940 — intervention group
Group type: EXPERIMENTAL
Intervention: Kisspeptin-54 (0.4 nmol/kg)
Number of subjects: 8
Study 17635940 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8
Study 15618248 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 0
Study 15618248 — intervention group
Group type: COMPARATOR
Intervention: Curettage
Number of subjects: 0
Study 11856794 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (core body temperature reduced to 33 degrees C within 2 hours and maintained for 12 hours)
Number of subjects: 77
Study 11856794 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 77
Study 10542978 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration with a 3000 ml syringe
Number of subjects: 43
Study 10542978 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometer A
Number of subjects: 43
Study 10542978 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometer B
Number of subjects: 43
Study 10542978 — intervention group
Group type: COMPARATOR
Intervention: Comparison with gold standard (CDS)
Number of subjects: 43
Study 7887841 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% apraclonidine
Number of subjects: 129
Study 7887841 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% apraclonidine
Number of subjects: 129
Study 2240297 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Behavior Checklist (FBC)
Number of subjects: 96
Study 2240297 — intervention group
Group type: COMPARATOR
Intervention: Introductory items as memory retrieval cues
Number of subjects: 96
Study 106982 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 antiinflammatory drugs
Number of subjects: 0
Study 106982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30428049 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimodivir 300 mg
Number of subjects: 292
Study 30428049 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimodivir 600 mg
Number of subjects: 292
Study 30428049 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimodivir 600 mg plus Oseltamivir 75 mg
Number of subjects: 292
Study 30428049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 30305657 — intervention group
Group type: EXPERIMENTAL
Intervention: dp‐ucMGP (desphospho‐uncarboxylated matrix Gla protein)
Number of subjects: 935
Study 26739013 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil
Number of subjects: 194
Study 26739013 — intervention group
Group type: COMPARATOR
Intervention: Conventional antihypertensive medication
Number of subjects: 194
Study 23607801 — intervention group
Group type: EXPERIMENTAL
Intervention: Using the Chinese language
Number of subjects: 512
Study 23607801 — intervention group
Group type: COMPARATOR
Intervention: Using the English language
Number of subjects: 512
Study 22500081 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐molecular‐weight fraction of edible mushroom shiitake extract
Number of subjects: 0
Study 22500081 — intervention group
Group type: COMPARATOR
Intervention: Placebo (negative control without active ingredients)
Number of subjects: 0
Study 22500081 — intervention group
Group type: COMPARATOR
Intervention: Meridol (positive control, AmF‐SnF(2))
Number of subjects: 0